[1] There are five genes involved: There are several therapeutic drugs that act as GUCAs, including linaclotide and plecanatide, which are guanylate cyclase-C receptor agonists.
These drugs increase the secretion of bicarbonate and chloride in the colon and potentially relieve visceral hypersensitivity in IBS-C patients.
This guanyl that triggers reduced blood flow through GTP to cGMP conversion.
The cGMP acts as a secondary messenger to target reduced blood flow pathways.
This pathway has been linked to several cardiovascular diseases, such as ADHF(acute decompensated heart failure) which Cinaciguat has been developed to target.